Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy - Slideshow (NASDAQ:ATHE) 2026-05-02
Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy Transcript
Las acciones de Alterity Therapeutics suben tras presentar datos positivos del ensayo de MSA en conferencia
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket - Albemarle (NYSE:ALB), Above Food Ingredients (NASDAQ:ABVE)